OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline
January 29, 2025
Host Chris Miglino interviews CEO Ilan Sobel. He talks about the way that their technology is used, the challenges that they face and how they make it economically viable.
January 29, 2025
January 14, 2025
July 16, 2024
July 9, 2024